With the support of
Project PMPTA22/00093 / IDI-20230060 funded by Plan de Recuperación, Transformación y Resiliencia – funded by the European Union – NextGenerationEU.
Gene Vector’s research and development activity in biotechnology is focused in developing and implementing advanced and scaled methods for GMP production of gene therapy elements to contribute to the progress of Gene Therapies. Some Gene Vector’s research activity is supported through its participation in projects awarded with competitive funding, such as:
TCR-READY
Optimised platform for the personalised production of transgenic TCR in T lymphocytes
With the support of
Project PMPTA23/00027 / IDI-20230956 funded by Plan de Recuperación, Transformación y Resiliencia – funded by the European Union – NextGenerationEU.
PROCELL
Development of a novel lentiviral Production Cell System for optimized Gene Therapy manufacturing
With the support of
Project PCPP2022-009650 funded by Ministerio de Ciencia e Innovación – Agencia Estatal de Investigación, MICINN-AEI/10.13039/501100011033 and the European Union-NextGenerationEU/PRTR.
